Mankind Pharma is engaged in the development, manufacture and marketing of a diverse range of pharmaceutical formulations.
Humanity IPO: The shares are currently trading at a premium of Rs 88 in the gray market to the top tranche of Rs 1,080 per share, at Rs 1,168
Mankind IPO: Mankind Pharma’s initial public offering, which was open for public subscription between April 25 and 27, was well received with the offering subscribed 15.32 times as it received offers for 42,95,12,902 shares against 2,80,41,192 shares offered.
Humanity IPO GMP today
Mankind shares are currently trading at a gray market premium of Rs 88, above the upper band of Rs 1,080 per share. Thus, shares on the gray market are currently trading at Rs 1,168 each, on April 29. This indicates that the company’s shares should be listed at a premium to its issue price on May 8, 2023. The premium fluctuates based on sentiment in the markets.
Humanity IPO: How to Check Award Status
Mankind Pharma will finalize the award by May 3, 2023. If not awarded, refunds will begin on May 4. Once awarded, the shares will be credited to your demat on May 5. Here’s how you can check the status of the assignment:
a) Go to the official website of the BSE or the Bombay Stock Exchange. The link is (https://www.bseindia.com/investors/appli_check.aspx)
b) This will take you to a page titled “Issue Request Status”
c) After landing on the page, click on “Equity” option
d) From the drop-down menu that will appear next to the issue name, select the ‘Mankind Pharma’ option
e) Enter your application number on the page
f) After that, write your permanent account number or PAN
g) Click on the Captcha that says “I’m not a robot” and click submit
h) After clicking on the option, details of the award status of your offer. The status will only be visible after the finalization of the allocation of shares.
Mankind Pharma IPO: Basic Details
Mankind Pharma is engaged in the development, manufacture and marketing of a diverse range of pharmaceutical formulations in various acute and chronic therapeutic areas, as well as several consumer healthcare products.
It has established several differentiated brands in the categories of condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations.
It has a pan-India marketing presence and operates 25 manufacturing plants across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D center with four units at IMT Manesar, Gurugram (Haryana) and Thane (Maharashtra).
The IPO was entirely an offer for sale (OFS) of 40.06 million shares by promoters and other existing shareholders. Its price range has been set at Rs 1,026-1,080 per share. In the Rs 4,326 crore IPO, a bidder bid for a minimum of one lot and a maximum of 13 lots. Many owned all 13 shares of Mankind Pharma.
The shares will be listed on the NSE and BSE on May 8, 2023.
Read all the latest business news, tax news and stock market updates here
.